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AbstrACt
Introduction Central lumbar spinal stenosis (LSS) 
is a common cause of pain, reduced function and 
quality of life in older adults. Current management 
of LSS includes surgery to decompress the spinal 
canal and alleviate symptoms. However, evidence 
supporting surgical decompression derives from 
unblinded randomised trials with high cross-over 
rates or cohort studies showing modest benefits. 
This protocol describes the design of the SUrgery for 
Spinal Stenosis (SUcceSS) trial —the first randomised 
placebo-controlled trial of decompressive surgery for 
symptomatic LSS.
Methods and analysis SUcceSS will be a 
prospectively registered, randomised placebo-
controlled trial of decompressive spinal surgery. 160 
eligible participants (80 participants/group) with 
symptomatic LSS will be randomised to either surgical 
spinal decompression or placebo surgical intervention. 
The placebo surgical intervention is identical to surgical 
decompression in all other ways with the exception of 
the removal of any bone or ligament. All participants 
and assessors will be blinded to treatment allocation. 
Outcomes will be assessed at baseline and at 3, 6, 
12 and 24 months. The coprimary outcomes will 
be function measured with the Oswestry Disability 
Index and the proportion of participants who have 
meaningfully improved their walking capacity at 3 
months postrandomisation. Secondary outcomes 
include back pain intensity, lower limb pain intensity, 
disability, quality of life, anxiety and depression, 
neurogenic claudication score, perceived recovery, 
treatment satisfaction, adverse events, reoperation rate 
and rehospitalisation rate. Those who decline to be 
randomised will be invited to participate in a parallel 
observational cohort. Data analysis will be blinded and 
by intention to treat. A trial-based cost-effectiveness 
analysis will determine the potential incremental cost 
per quality-adjusted life year gained.
Ethics and dissemination Ethics approval has been 
granted by the NSW Health (reference:17/247/POWH/601) 
and the Monash University (reference: 12371) Human 
Research Ethics Committees. Dissemination of results will 
be via journal articles and presentations at national and 
international conferences.
trial registration number ACTRN12617000884303; Pre-
results.
IntroduCtIon 
Lumbar spinal stenosis (LSS) is a common 
source of pain and reduced function in those 
over the age of 50.1 The condition is attributed 
to a reduction in the diameter of the lumbar 
spinal canal from age-related degenera-
tive changes of the surrounding structures, 
including the intervertebral discs, facet joints 
and ligaments.2–4 Symptoms typically include 
neurogenic claudication, which is defined 
as pain, paraesthesia and/or fatigue in the 
gluteal area and/or legs that is aggravated by 
walking, and relieved by bending forward or 
sitting.5 
In the Japanese population, approximately 
three-quarters of those over 40 years of age 
have MRI signs of moderate central canal 
stenosis (ie, narrowing by one-third of the 
canal area).3 Thirty per cent have severe 
stenosis (narrowing by two-thirds), but only 
around one-fifth of those report clinical 
symptoms.3 A case-multiple control study 
from the USA including 126 individuals (50 
strengths and limitations of this study
 ► This will be the first randomised placebo-controlled 
trial of surgery for symptomatic lumbar spinal ste-
nosis (LSS).
 ► Participants and study assessors will be blinded to 
treatment allocation.
 ► The placebo intervention will resemble surgical de-
compression, but exclude removal of the bone and 
ligament (ie, to increase the diameter of the spinal 
canal).
 ► The findings of this study will provide level 1 evi-
dence for the treatment efficacy, safety and cost-ef-
fectiveness of decompression for LSS.
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with a clinical diagnosis of lumbar stenosis, 44 with back 
pain and no diagnosis of stenosis and 32 with no pain) 
found no correlation between imaging findings and 
clinical diagnosis of stenosis, with approximately 50% 
(n=13/32) of the asymptomatic participants being diag-
nosed with stenosis by blinded assessors.6 The diagnosis 
of LSS, therefore, requires both the presence of clinical 
symptoms (ie, neurogenic claudication) and evidence of 
stenosis on diagnostic imaging (eg, MRI).3 Current guide-
lines recommend symptomatic LSS be managed initially 
with non-operative treatment,7 including oral medica-
tion (ie, non-steroidal anti-inflammatory drugs and anal-
gesics) and physical therapies (eg, exercise therapy or 
manual therapy).8 If patients with symptomatic LSS fail 
to improve with non-operative treatment, referral for 
surgical assessment is recommended.7 9
Surgical management of LSS involves decompression of 
the spinal canal via laminectomy or laminotomy.10–12 The 
procedure is the most common form of spinal surgery in 
adults over the age of 65.13 Recent data from the USA 
estimate an adjusted rate of lumbar stenosis surgery of 
135.5 per 100 000 Medicare beneficiaries, with a resulting 
aggregated hospital bill of US$1.65 billion per year. The 
evidence supporting this practice is, however, inconclu-
sive. The latest Cochrane review assessing the efficacy of 
surgery compared with non-surgical care for this popu-
lation included five randomised controlled trials (643 
participants) and concluded there is low quality evidence 
that surgery provides little benefit after 2 years follow-up 
compared with non-surgical treatment (a difference in 
the Oswestry Disability Index (ODI) of 4.43, which is less 
than the accepted minimally clinically important differ-
ence of 15).14 This is in part attributed to the method-
ological limitations of existing trials, including lack of 
participant and assessor blinding, imprecise results due 
to small samples and high treatment crossovers.8 15–18 
For example, the Spine Patient Outcomes Research 
Trial (SPORT) published in 2008 evaluated the effects of 
surgery for spinal canal stenosis19 in an open randomised 
parallel group design. Over one-third of participants 
assigned to surgery did not undergo surgery, and almost 
half (43%) of those assigned to non-operative manage-
ment underwent surgery. Given patients often have 
strong preferences for one treatment over the other, 
treatment crossovers are common in pragmatic open 
trials of surgical interventions.19 20 The results of the 
as-treated analysis in the SPORT trial favoured surgery 
in reducing pain and disability, but these results were 
not confirmed in the intention-to-treat analyses. A more 
recent trial by Delitto et al that randomised 169 patients 
to either decompressive surgery or physical therapy20 also 
failed to find any clinically important differences in pain 
improvement or physical function between treatment 
groups. Given the lack of robust evidence confirming the 
superiority of surgery compared with non-surgical care; 
the benefits of surgery observed in clinical practice might 
be attributable to non-specific effects, including regres-
sion to the mean and the placebo effects associated with 
invasive procedures.21 These findings highlight the need 
for a placebo-controlled trial of surgical decompression 
in this population.
The importance of a placebo surgical intervention is 
that it is indistinguishable (ie, to the participant) from 
the traditional surgical procedure in many aspects. These 
include preoperative and anaesthetic management; inci-
sion length and surgical dissection; and postoperative 
discomfort and management. By design and intention, 
the observable differences between participants receiving 
placebo surgical intervention and those receiving the 
traditional surgical procedure are more reliably due to 
the procedure itself and not the events surrounding the 
procedure. In the case of lumbar surgical decompres-
sion, this means that the placebo surgical intervention 
must include muscle dissection down to the bone of the 
lumbar lamina, but no removal of bone or ligamentum 
flavum. Placebo interventions also differ from sham in 
that a sham intervention might only involve a skin inci-
sion; falling short of replicating the experience of the 
traditional surgical procedure, including the absence of 
postsurgical pain from muscle dissection, or any potential 
benefits from denervation effects of surgical dissection.
Placebo-controlled trials of surgical interventions are 
not new. In the late 1950s, two landmark randomised 
trials for patients with severe angina pectoris compared 
the common practice of internal mammary artery liga-
tion to placebo surgical intervention.22 23 The observation 
that the placebo surgical intervention resulted in similar 
and sustained symptom relief as true ligation surgery 
disproved the rationale of the procedure to increase 
coronary artery blood flow. A recent systematic review 
identified a total of 53 randomised placebo-controlled 
trials of surgery published between 1946 and 2013, with 
about half showing the index procedure was superior to a 
placebo comparator, while the other half showed no supe-
riority of the surgical procedure.24 The review also found 
that placebo trials can be safe, and that placebo interven-
tions are, in general, associated with less frequent and less 
severe adverse events than the experimental group.
Given the growing rates of surgical management of symp-
tomatic LSS and the inconclusive evidence supporting its 
efficacy, we have designed and will conduct the first place-
bo-controlled trial of surgical decompression for this 
population. The aim of the SUrgery for Spinal Stenosis 
(SUcceSS) trial is to evaluate the efficacy, safety and 
cost-effectiveness of decompressive surgery for people 
with severe LSS who have failed to respond to non-oper-
ative care. We will evaluate relevant participant outcomes 
related to LSS, including disability, walking capacity, pain, 
quality of life, serious adverse events (SAEs) and reoper-
ation rates. Our study hypothesis is that decompression 
surgery is more effective, more cost-effective and safer 
than placebo surgical intervention in improving pain and 
function in patients with LSS. The study will also include 
a parallel observational study of eligible participants who 
decline to be randomised to the placebo-controlled trial 
to test for any selection bias.




This paper describes a research protocol for the SUcceSS 
trial, a prospectively registered, randomised placebo-con-
trolled trial of decompressive spinal surgery for LSS. 
The participants, investigators (other than the surgical 
team performing the procedures) and outcome asses-
sors will be blinded to treatment allocation. The protocol 
was developed in accordance with Standard Protocol 
Items: Recommendations for Interventional Trials and 
Template for Intervention Description and Replication 
statements.25 26 The study design appears in figure 1.
Participants and recruitment
Consecutive patients who present to one of the study 
surgeons in New South Wales or Victoria, Australia will be 
assessed for eligibility and invited to participate. All study 
surgeons will be qualified orthopaedic spine surgeons 
or neurosurgeons, and are required to have current 
registration to perform spinal decompression surgery in 
Australia.
Inclusion criteria
Participants will need to meet all the following inclusion 
criteria:
 ► Be 50 years of age or older.
 ► Present with neurogenic claudication for at least 
3 months. Neurogenic claudication is defined as pain, 
numbness and/or fatigue below the gluteal line with 
or without back pain (if back pain is present, leg 
pain is greater than back pain) that is precipitated by 
walking and alleviated by sitting or other posture of 
lumbar flexion.
 ► Have grades C or D stenosis as defined by Schizas et 
al27 indicating occlusion (absent cerebrospinal fluid 
signal) of the central lumbar spinal canal at one or 
two levels on T2-weighted MRI or CT myelogram.
Figure 1 The flow chart of the SUcceSS study design. SUcceSS, SUrgery for Spinal Stenosis. 
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 ► Be considered by a study surgeon to be in need of 
single or dual-level decompressive surgery.
 ► Have not improved with non-surgical treatment (eg, 
physiotherapy, medication).
Exclusion criteria
Participants will be excluded if they meet any of the 
following criteria:
 ► Are pregnant.
 ► Are under a worker’s compensation claim.
 ► Have been diagnosed with serious spinal pathology 
including: cancer, infection, cauda equina syndrome, 
spinal fracture.
 ► Present with active Paget’s disease of the spine.
 ► Have a diagnosis of lumbar instability defined as 
more than 4 mm translation or 10° of angular motion 
between flexion and extension on upright lateral radi-
ographs (to exclude participants who might need to 
undergo concurrent surgical fusion).
 ► Have had previous lumbar spine surgery at the same 
levels.
 ► Inadequate English to complete outcome measures.
 ► Motor deficit related to lumbar compression (Medical 
Research Council grades 0–4) and the motor deficit 
interferes with walking ability.
 ► Presence of significant scoliosis (Cobb angle >25°) or 
other spinal deformities.
 ► Presence of known or demonstrated peripheral 
vascular disease causing vascular claudication, that 
is, claudication accompanied by absent foot pulse or 
vascular insufficiency detected with Doppler Ultra-
sound or CT angiography.
 ► Meyerding classification grade 2 or greater 
spondylolisthesis.
 ► Symptomatic hip disease with symptoms reproduced 
with external or internal rotation of the hip joint.
 ► Cognitive impairment interfering with participant’s 
ability to give full and informed consent or complete 
the baseline or follow-up assessments.
If a study surgeon determines the participant has met 
the trial eligibility criteria, the participant will be provided 
with information about the trial and asked if they 
consent for a study researcher to contact them. As part 
of consent, participants will be informed they could be 
allocated on a 50:50 basis to receive either conventional 
surgical decompression or placebo surgical interven-
tion (no decompression). A researcher will then contact 
them, provide detailed trial information, obtain written 
informed consent and collect all baseline assessments. A 
subject/participant identification (ID) number will then 
be allocated and the participant booked for surgery at the 
earliest available date. When surgery cannot be sched-
uled within 6 weeks from baseline, baseline assessments 
will be repeated to ensure a maximum of 6 weeks from 
baseline assessment to randomisation. Eligible patients 
who do not consent to participate in the randomised trial 
will be invited to participate in a parallel observational 
cohort. Participants who consent to participate in the 
observational cohort will be followed up for the dura-
tion of the trial and the same outcome measures will be 
collected at all time points.
study treatment
On the scheduled day of surgery, each participant will be 
admitted to the hospital of the recruiting study surgeon 
and follow the hospital’s routine admission protocol. 
Participants will receive general anaesthesia, venous 
thromboembolism prophylaxis and prophylactic antibi-
otics. Based on each individual surgeon’s standard surgical 
practice, a local anaesthetic may be infiltrated into the 
subcutaneous tissues, with a single midline or dual para-
median longitudinal skin incision made through the skin 
and adipose layers. The posterior spinal muscles will then 
be dissected in a subperiosteal fashion to expose lumbar 
laminae and self–retaining retractors placed. Participants 
will be randomised to treatment groups following muscle 
dissection. If the patient is randomised to placebo surgical 
intervention, the surgeon will progress no further and 
close the wound. In this case, the lumbar spinal canal 
will not be entered or the dural sac decompressed. If 
the patient is randomised to receive surgery involving 
decompression, the surgeon will proceed to remove bone 
from the lamina, and underlying ligamentum flavum in 
order to enter the lumbar spinal canal and decompress 
the dural sac. Following the decompression or placebo 
surgical intervention, routine postoperative care will 
follow as per the standard of care from the operating 
hospital (eg, mobility advice, wound care).
randomisation
Central randomisation will be used to ensure concealment 
of treatment allocation. An interactive voice response 
will be used for automatic, 24 hours/day, 7 days/week 
allocation of participants and delivered to participating 
surgeons at the time of surgery. The randomisation will 
be obtained by a study trained theatre clinician who 
will contact the central randomisation service following 
muscle dissection, but prior to decompression. Randomi-
sation will be by random permuted blocks of 4 and 6 and 
stratified by surgeon.
blinding
Participants, assessors and investigators (other than the 
treating surgical team) will be blinded to treatment allo-
cation. Randomisation will occur in the surgical theatre 
to eliminate treatment bias by any of the surgical team 
prior to the procedure. Members of the surgical team 
will not be involved in patient care after the procedure. 
Arrangements will be made for surgical colleagues who 
are unaware of the treatment given to provide postoper-
ative care.
data collection
Blinded research staff will collect all baseline data 
including demographic data (eg, work status, socio-
economic status, symptom duration, etc) and outcome 
data, SAEs, and hospital admissions and medications. 
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Outcomes will be collected at baseline and at 3, 6, 12 
and 24 months (with adverse events and hospital admis-
sions additionally collected at 9, 15, 18 and 21 months). 
All research staff will be trained to ensure data accuracy, 
consistency and completeness.
Primary outcomes
The coprimary outcomes will be the function measured 
with the ODI score28; and the proportion of participants 
who have meaningfully improved their walking capacity.29 
Our selection of coprimary outcomes reflects the two 
main complaints of patients with LSS: walking capacity 
and function. The ODI is a self-reported questionnaire 
commonly used to assess function in people with spinal 
conditions, including LSS.19 20 30 The outcome has been 
validated in this population, showing good postsurgery 
responsiveness, excellent internal consistency (Cron-
bach’s alpha of 0.9) and test–retest reliability (Intra-
class correlation (ICC): 0.89).31 The ODI is also strongly 
correlated with patient satisfaction after surgery.31
The self-reported walking capacity measure has also 
been validated in people with LSS and neurogenic claudi-
cation, showing strong correlation with the ODI walking 
section (Spearman r: 0.64) and self-paced walking test 
(Spearman r: 0.65; ICC: 0.68).32 33 Meaningful improve-
ment will be defined as a score of 6 or 7 on the walking 
capacity change scale: ‘How would you say your walking 
capacity is today compared with immediately before 
surgery?’, where 1 is ‘a great deal worse’ and 7 is ‘a great 
deal better’.29 Coprimary outcomes will be measured 
at baseline (ODI only), 3, 6, 12 and 24 months. The 
primary outcome time point will be 3 months because 
the beneficial effects of definitive surgical decompres-
sion are likely to be apparent by then, and patients with 
poor clinical response are more likely to undergo further 




1. Walking ability, using the walking section of the 
ODI,29 will be measured at baseline, 3, 6, 12 and 24 
months.
2. Assessment of neurogenic claudication: claudica-
tion will be measured using the Swiss Spinal Stenosis 
Questionnaire31 and will be measured at baseline, 3, 
6, 12 and 24 months. Results of the symptom severity 
and functional subscales of the Swiss Spinal Stenosis 
Questionnaire will be separately reported.
3. Average lower limb pain in the past week will be 
measured using the 11-point Numerical Rating Scale 
(NRS), where 0 is ‘no pain’ and 10 is ‘worst possible 
pain’,34 35 at baseline, 3, 6, 12 and 24 months.
4. Average low back pain in the past week will be mea-
sured using the 11-point NRS scale, where 0 is ‘no 
pain’ and 10 is ‘worst possible pain’,34 35 at baseline, 
3, 6, 12 and 24 months.
5. Quality of life: the Assessment of Quality of Life ques-
tionnaire will be used to assess the quality of life and 
to estimate quality-adjusted life years (QALYs) for the 
cost-effectiveness analyses.36 37 It will be measured at 
baseline, 3, 6, 12 and 24 months.
6. Self-reported perceived recovery will be measured us-
ing a 7-point Likert scale where 1 is ‘worse than ever’ 
and 7 is ‘completely recovered’38 will be measured at 
3, 6, 12, and 24 months.
7. Satisfaction with surgery: measured using section XIII 
of the Swiss Spinal Stenosis Questionnaire, which asks 
‘how satisfied are you with the overall result of your 
back operation’ where 1 is very satisfied and 4 is very 
dissatisfied31 will be measured at 3 months only.
8. Reoperation and rehospitalisation rates: data on hos-
pital and/or privately funded healthcare visits will be 
collected over the phone via the use of a diary which 
the participant will keep and complete at all listed 
time points. These data will be measured at 3, 6, 9, 
12, 15, 18, 21 and 24 months.19
9. Healthcare utilisation will be collected from partici-
pant diaries for the cost-effectiveness analysis at 3, 6, 
9, 12, 15, 18, 21 and 24 months.
10. Adverse events will be collected from participant di-
aries at screening, baseline, 3, 6, 9, 12, 15, 18, 21 and 
24 months following treatment.
11. Surgical decompression and placebo intervention fi-
delity: an MRI scan will be performed on a random 
20% selection of those receiving the surgical decom-
pression or placebo interventions to assess the fidelity 
of the two procedures. This will be completed at the 
24-month follow-up only.
other data collected
Demographic information, clinical data and expecta-
tion of treatment outcome will be collected at baseline. 
These measures include an expectation of satisfaction 
with treatment outcome in terms of pain and walking 
capacity measured as: ‘How much pain relief would you 
expect from treatment?’ and ‘How much improvement in 
your walking capacity would you expect from treatment?’. 
Participants will be asked to rate their expectation of 
change in walking capacity and expected pain relief 
using a 7-point Likert scale where 1 is ‘no improvement 
expected’ and 7 is ‘full recovery expected’.39 Anxiety and 
depression will be measured at baseline via the Hospital 
Anxiety and Depression Scale.40 Blinding fidelity will be 
assessed by asking the patient ‘which study group do you 
think you were in?’ (decompression surgery, placebo 
intervention, do not know) and will be measured at 
hospital discharge following surgery and at 3 months.
Adverse events
A standard operating procedure (SOP) for clinical trial 
safety will be used to guide the data collection of adverse 
events, SAEs, suspected and unexpected serious adverse 
reactions in this study. This SOP will describe in detail 
the actions to be taken should adverse events occur and 
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the relevant timelines. Events will be classified according 
to their attribution (not related, doubtful, possible, prob-
able and very likely) and severity (mild, moderate or 
severe). Risks and complications of surgical decompres-
sion are rare and may include cerebrospinal fluid leak, 
postoperative instability of the operated level, infection, 
nerve root damage and bleeding.
SAEs are defined as any event that is life threatening, 
results in death, hospitalisation or significant disability.19 
Any SAE will be immediately reported to the data moni-
toring committee by a notified study member. The 
steering committee will investigate the nature of the 
adverse event and whether unblinding of treatment allo-
cation is necessary. The ethics committee will also be 
informed of all SAEs.
treatment fidelity
All staff involved in the delivery of the study will be 
required to undertake research training. This will include 
study surgeons, anaesthetists and nurses involved in the 
care of participants. Regular research meetings will be 
conducted with study staff, and site visits of participating 
hospitals completed. Study patients will be provided with 
a study pamphlet that can be shown to their other treating 
healthcare professionals (eg, physiotherapists, general 
practitioners, etc). The pamphlet explains the trial and 
their participation in it.
unblinding
Unblinding will be carried out in the case of SAEs where 
knowledge of the participant’s treatment allocation is 
necessary for further medical management of the partic-
ipant, or in cases where the participant requests to be 
unblinded due to his/her withdrawal from the study. 
Following unblinding, the following information must be 
provided: the reason for unblinding, details of the clini-
cian, the date and time the decision was made, and any 
supporting documentation. Regardless of unblinding, a 
follow-up schedule for data collection will be attempted, 
to enable a full analysis of all participant data on an inten-
tion-to-treat basis. At the end of the trial, participants may 
be notified of the study results and treatment allocation 
if they wish to be.
data integrity
A data monitoring committee has been convened and will 
overview data collection and integrity. Data collected by 
the trained research staff will be directly entered into a 
custom-built Electronic Data Capture program at the time 
of data collection, with a prompt for double checking of 
the accuracy of the primary outcomes. Any inconsisten-
cies in the data will be explored and resolved. Any data 
completed by participants via questionnaires will be 
recorded into the database by the research assistant.
A database will be backed-up regularly on a secure 
network and compliant to the Note for Guidance on Good 
Clinical Practice, according to our data management 
plan. Study personnel will only be able to access the data-
base with a personal login and password.
retention of documents
The study investigators will maintain adequate and accu-
rate records to enable the conduct of the study to be fully 
documented and the study data to be subsequently veri-
fied. These documents will be classified into two separate 
categories (1) investigator’s study file and (2) partici-
pant clinical source documents. The investigator’s study 
file will contain the protocol/amendments, schedule of 
assessments, independent ethics committee/institutional 
review board and governmental approval with corre-
spondence, sample informed consent, staff curriculum 
vitae and authorisation forms and other appropriate 
documents/correspondence.
Should the study investigators wish to assign the study 
records to another party or move them to another loca-
tion, the sponsor must be notified in advance. After the 
completion of the study, study data will be archived by the 
sponsor for a minimum of 15 years.
statistical analysis
Treatment effectiveness analyses of randomised trial data 
will be blinded and performed on an intention-to-treat 
basis. Statistical significance will be defined as p<0.025 on 
the basis of a two-sided test (Bonferroni correction for 
co-primary outcomes). The 3-month follow-up will be the 
primary endpoint. All between-group differences at all 
follow-up time points will be analysed with linear regres-
sion for continuous outcomes and logistic regression for 
dichotomous outcomes. Adjusted (sensitivity) and unad-
justed (main) analyses will be presented for the main 
confounders. Heterogeneity between recruiting hospitals 
will be calculated and adjusted for in sensitivity analyses by 
including hospital as a covariate in the models. To eluci-
date if any sampling bias is present in the trial, baseline 
characteristics of participants in the randomised cohort 
will be contrasted with those in the observational cohort.
In addition to a primary and secondary outcome anal-
yses, a formal interim analysis will be conducted after 
two-thirds of participants (n=107) have completed the 
3-month follow-up of the coprimary outcome measure-
ments (primary endpoint). The interim analysis will be 
performed by a blinded statistician who can recommend 
to the data monitoring committee that the trial is termi-
nated early for efficacy, defined as a between-group differ-
ence greater than 3 SD. A recommendation to terminate 
the study early could also be made if there is proof beyond 
reasonable doubt that the intervention or placebo cause 
an unacceptable net harm. The trial will not be termi-
nated on the grounds of futility.
Sample size calculation was based on the between-group 
difference at all follow-ups, on coprimary outcomes. A 
sample size of 80 per group (total of 160 participants) 
will achieve 90% power to detect a minimum clinically 
important difference of 15 points (of a total of 100 
points) on ODI (SD: 18) and difference between groups 
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in proportion of participants who have improved in the 
walking change score (ie, 6 or 7 on the Likert scale) of 30% 
(ie, assuming 30% of participants in the placebo group 
and 60% in the intervention group will have improved).29 
This sample size allows for a 15% loss to follow-up rate; 5% 
crossover between groups at 3 months19 20 41 and provides 
enough power to detect an absolute difference of 20% 
in reoperation rates over 2 years (the current reopera-
tion rate for decompressive surgery is 7% and the rate of 
surgery in the non-operative groups of previous studies is 
approximately 50%).42
Cost-effectiveness analysis
In the event of an observed positive treatment effect, a 
cost-effectiveness analysis will be conducted. Interven-
tion costs (staff, consumables, equipment, etc) will be 
ascertained from financial statements from participating 
sites. Hospital admissions over the course of the study in 
both patient arms will be recorded in patient diaries and 
costed on the basis of published diagnosis-related group 
cost weights. Non-hospital services will be costed through 
individually linked Medicare data; costs of non-hospital 
medications will be determined through individually 
linked Pharmaceutical Benefits Scheme data. The aggre-
gate of relevant costs to patients in both arms will be used 
to calculate the incremental healthcare costs incurred 
(or cost savings). QALYs will be used to determine effec-
tiveness, and converted into a utility index, using data 
derived from the Australian population. Average differ-
ences in QALYs will be estimated between treatment and 
control arms. An incremental cost-effectiveness ratio will 
be calculated based on the ratio of incremental costs over 
incremental QALYs. Sensitivity analyses will be conducted 
to determine the robustness of the results to key assump-
tions made in the analyses.
Patient and public involvement
Consumer representatives were involved in different 
stages of the design of this trial. Prior to the protocol 
development phase, patients presenting to neurosur-
geons or orthopaedic surgeons with LSS and indication 
for surgical decompression were surveyed regarding their 
views on the value of such a study and their willingness to 
participate in this trial. Members of the Consumer Advi-
sory Group of the Australia and New Zealand Musculo-
skeletal (ANZMUSC) Clinical Trials Network were also 
consulted and asked to provide feedback on the protocol 
during its development phase.
Ethics and dissemination
The SucceSS trial will be undertaken across multiple sites 
in New South Wales and Victoria, Australia and a report of 
the trial findings will be prepared according to the consort 
Consolidated Standards of Reporting Trials statement. 
Authorship eligibility guidelines of publications arising 
from the SUcceSS study will follow those outlined by 
the International Committee of Medical Journal Editors 
(http://www. icmje. org/). Findings from the study will be 
disseminated via journal publications and presentations 
at national and international conferences. The study is 
sponsored by The University of Sydney, Australia and 
centrally coordinated and managed by staff based at the 
Kolling Institute/Northern Clinical School. The sponsor 
has no role in the design of the trial. A Steering Commitee 
is responsible for study conception, design, protocol 
refinement and providing the scientific direction of the 
study. Members of the committee have expertise in the 
conduct of large, high-quality randomised trials, surgical 
trials and placebo trials of surgery. The current protocol 
is V.3.0 (13/07/2018). Any modifications to the protocol, 
which may impact the study design and conduct, potential 
benefit or harm of the participants, will require a formal 
amendment to the protocol. Such amendment will be 
agreed on by the Steering Commitee and approved by 
the ethics committee prior to implementation. The study 
adheres with the Australian National Health and Medical 
Research Council ethical guidelines for human research.
dIsCussIon
This manuscript outlines the design of SUcceSS, the first 
randomised placebo-controlled trial of surgery for LSS. 
The trial has been endorsed by the ANZMUSC Clinical 
Trials network; reflecting its robust design. The design of 
the SUcceSS trial is the result of an ongoing and close 
collaboration among researchers, health economists, 
biostatisticians, consumers and surgeons. SUcceSS will 
address the main limitations of previous surgical trials via 
its unique study design and use of a placebo arm. The 
inclusion of a placebo surgical intervention will ensure 
blinding of participants and assessors to treatment allo-
cation, limiting treatment crossover and account for any 
placebo effect associated with decompression surgery. As 
a result, the study will provide high-quality evidence for 
the efficacy of decompressive surgery in treating LSS.
Our trial conforms to the ethical framework for the use 
of placebo procedures in clinical trials proposed by Horng 
and Miller.43 According to the framework, the conduct of 
a placebo-controlled trial is ethical when: (1) it involves 
an important research question that cannot be answered 
without a placebo control. This is the case in surgical trials 
of LSS, given most commonly used outcome measures 
are self-reported and blinding of participants is impos-
sible in ‘open-label’ trials or those involving a no-treat-
ment control arm. In this case, there is no alternative to 
placebo and no other sufficiently rigorous trial design 
that has less risk (any other option will affect blinding); 
(2) although the risks are greater than minimal they are 
likely to be equal in both groups. Past research has shown 
that the risk associated with placebo surgery is not greater 
than that of active surgery. Moreover, there are no antici-
pated extra risks and hazards to patients allocated to the 
placebo surgical intervention group, since there will be 
no bone removal24; (3) risks associated with the placebo 
and active interventions do not exceed a threshold of 
acceptable research risk. We have been working closely 
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with an ethicist to ensure all potential risks involved with 
participating in any of the interventions are appropri-
ately disclosed to the participant; (4) any risk in either 
arm is minimised by involving highly experienced and 
trained surgeons, following a carefully designed protocol 
and establishing a data monitoring committee and (5) 
informed consent is sought prior to any study-related 
procedures being conducted.
One debate is whether the comparator for full surgical 
treatment should be placebo or sham surgery. Placebo 
surgical intervention is a surgical intervention performed 
in exactly the same way as the procedure under investiga-
tion, but omitting the critical surgical element or mecha-
nism, given the mechanism by which it potentially obtains 
benefit has been questioned.44 Placebo is designed to 
cause the same effects on the participant as definitive 
surgical treatment (such as discomfort), except for the 
critical element (canal decompression). It differs from 
a sham intervention which has only superficial similarity 
with definitive surgery, such as skin incision only. Placebo 
surgical intervention is frequently associated with larger 
beneficial effects on the participant than a sham. Further-
more, placebo surgical intervention also allows for more 
reliable blinding of patients and assessors, than any other 
comparator (ie, no treatment, non-surgical care and 
sham). Therefore, to ensure a more robust design and 
given we currently lack strong evidence supporting the 
therapeutic mechanism of decompression surgery (ie, 
widening of the spinal canal), the SucceSS trial team have 
opted to include a placebo surgical intervention.
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